Most of the neurodegenerative diseases that afflict humans manifest with the intraneuronal accumulation of toxic proteins that are aggregate-prone. Extensive data in cell and neuronal models support the concept that such proteins, like mutant huntingtin or alpha-synuclein, are substrates for macroautophagy (hereafter autophagy). Furthermore, autophagy-inducing compounds lower the levels of such proteins and ameliorate their toxicity in diverse animal models of neurodegenerative diseases. However, most of these compounds also have autophagyindependent effects and it is important to understand if similar benefits are seen with genetic strategies that upregulate autophagy, as this strengthens the validity of this strategy in such diseases. Here we review studies in vertebrate models using genetic manipulations of core autophagy genes and describe how these improve pathology and neurodegeneration, supporting the validity of autophagy upregulation as a target for certain neurodegenerative diseases.
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Clearance of aggregate-prone proteins by autophagy
Many neurodegenerative diseases, such as Alzheimer's disease (AD), Huntington's diseases (HD), Parkinson's disease (PD) and Dementia with Lewy bodies (DLB), share the similar neuropathology of mutant protein misfolding and aggregation in the brain (Bancher et al., 1989; DiFiglia et al., 1997; Spillantini et al., 1998) . In cells, mutant proteins associated with neurodegenerative diseases can form various oligomeric species and insoluble aggregates. We now know that many of the mutations confer new, toxic, gain-of-function properties on the proteins that eventually cause the death of specific neuronal populations in these diseases (Arrasate et al., 2004; Ashkenazi et al., 2017; DiFiglia et al., 1997) . Thus, reduction in the levels of different species (soluble and insoluble) of the misfolded proteins can reduce the toxic burden in cells and prevent neuronal death (Berger et al., 2006; Ravikumar et al., 2002) .
The ubiquitin-proteasome system and macroautophagy (hereafter autophagy) are the main degradative pathways within cells. Autophagy is an efficient process that clears cytoplasmic oligomeric species of the toxic proteins that are not accessible to the proteasome (Ciechanover and Kwon, 2015; Rubinsztein, 2006) . Overall, autophagy induction shows beneficial effects by decreasing both the soluble and the insoluble forms of the misfolded proteins. Autophagy may also be able to reduce the levels of intraneuronal aggregates in some diseases, like spinocerebellar ataxia type 3, by enabling the removal of intracytoplasmic species, which are in equilibrium with the mutant protein in the nucleus. Several molecules have been reported to induce autophagy and show beneficial effects in animal models of neurodegenerative diseases (Menzies et al., 2017; Rubinsztein et al., 2012) . However, most of these compounds also have autophagy-independent effects and it is important to understand if similar benefits are seen with genetic strategies that upregulate autophagy, as this strengthen the validity of this strategy in such diseases.
There is accumulating genetic support for the benefits of autophagy induction in vivo in models of neurodegeneration using mammalian autophagy proteins (ATG) that are involved in the synthesis of autophagosomes. In this review, we will briefly summarize small and nonsmall molecule inducers of autophagy and focus on autophagy genes that induce autophagy and reduce toxicity in animal models of AD, HD, and PD.
